Empirical antimicrobial therapy for traveler's diarrhea.
Over 7 million cases of traveler's diarrhea, defined as the passage of > or = 3 unformed stools in a 24-h period, occur each year among visitors to developing countries. Bacterial enteric pathogens are the most common etiologic agents isolated. Preliminary clinical results for patients with diarrhea predominantly caused by Campylobacter species have shown that azithromycin may be an effective alternative to fluoroquinolones for the treatment of traveler's diarrhea.
Adachi
J A
JA
Division of Infectious Diseases, Department of Internal Medicine, University of Texas-Houston Medical School, Houston, TX 77030, USA.
Ostrosky-Zeichner
L
L
DuPont
H L
HL
Ericsson
C D
CD
D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D017963:Azithromycin / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy; D002169:Campylobacter Infections / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy*; D024841:Fluoroquinolones; D006801:Humans; D014195:Travel; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D017963:Azithromycin